CA3068305A1 - Kinase inhibitors and methods for making and using - Google Patents
Kinase inhibitors and methods for making and using Download PDFInfo
- Publication number
- CA3068305A1 CA3068305A1 CA3068305A CA3068305A CA3068305A1 CA 3068305 A1 CA3068305 A1 CA 3068305A1 CA 3068305 A CA3068305 A CA 3068305A CA 3068305 A CA3068305 A CA 3068305A CA 3068305 A1 CA3068305 A1 CA 3068305A1
- Authority
- CA
- Canada
- Prior art keywords
- pyrazol
- compound
- piperidin
- carboxamide
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762526838P | 2017-06-29 | 2017-06-29 | |
| US62/526,838 | 2017-06-29 | ||
| PCT/US2018/040021 WO2019006126A1 (en) | 2017-06-29 | 2018-06-28 | KINASE INHIBITORS AND METHODS OF MAKING AND USING THEM |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3068305A1 true CA3068305A1 (en) | 2019-01-03 |
Family
ID=62976284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3068305A Pending CA3068305A1 (en) | 2017-06-29 | 2018-06-28 | Kinase inhibitors and methods for making and using |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10590121B2 (https=) |
| EP (1) | EP3645525A1 (https=) |
| JP (2) | JP7167069B2 (https=) |
| CN (1) | CN111032642B (https=) |
| CA (1) | CA3068305A1 (https=) |
| WO (1) | WO2019006126A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3068305A1 (en) * | 2017-06-29 | 2019-01-03 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and methods for making and using |
| WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| EP3898616B1 (en) | 2018-12-20 | 2024-10-02 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| JP7676308B2 (ja) * | 2018-12-20 | 2025-05-14 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド |
| US11390604B2 (en) * | 2019-03-08 | 2022-07-19 | Hoffmann-La Roche Inc. | Imidazole-pyrazole derivatives |
| WO2021018118A1 (en) * | 2019-07-29 | 2021-02-04 | Janssen Pharmaceutica Nv | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 1 proteins |
| US12540129B2 (en) | 2019-08-02 | 2026-02-03 | Amgen Inc. | KIF18A inhibitors |
| WO2021026099A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| WO2021035257A1 (en) * | 2019-08-21 | 2021-02-25 | The Scripps Research Institute | Monocyclic agonists of stimulator of interferon genes sting |
| CN110592056A (zh) * | 2019-09-19 | 2019-12-20 | 昆明理工大学 | 噬菌体裂解酶复合粉剂及其制备方法和应用 |
| CN114981259B (zh) * | 2020-01-22 | 2024-06-18 | 豪夫迈·罗氏有限公司 | 新型杂环化合物 |
| AR121717A1 (es) * | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| US20230295146A1 (en) * | 2020-07-24 | 2023-09-21 | The University Of Rochester | Inhibitors of interleukin-1 receptor-associated kinases 1 and 4 |
| JP2024506021A (ja) * | 2021-02-07 | 2024-02-08 | エフ． ホフマン－ラ ロシュ アーゲー | 新規ヘテロアリール置換イミダゾール誘導体 |
| WO2022197575A1 (en) * | 2021-03-17 | 2022-09-22 | Merck Sharp & Dohme Llc | Heteroaroyl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| WO2023088435A1 (zh) * | 2021-11-19 | 2023-05-25 | 成都奥睿药业有限公司 | 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用 |
| JP2025513716A (ja) | 2022-03-23 | 2025-04-30 | ライジェル・ファーマシューティカルズ・インコーポレイテッド | Ｉｒａｋ阻害剤としてのピリミド－２－イル－ピラゾール化合物 |
| AU2024214768A1 (en) * | 2023-01-30 | 2025-08-07 | The Johns Hopkins University | 18 f-labeled pet radiotracers for imaging macrophage colony stimulating factor 1 receptor |
| CN118027009B (zh) * | 2024-04-15 | 2024-07-12 | 北京师范大学 | 一类靶向于csf1r激酶的苯基酰胺类化合物及其应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| EP0431519B1 (en) | 1989-12-04 | 1994-06-15 | G.D. Searle & Co. | System for transdermal albuterol administration |
| US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| DE69228827T2 (de) | 1991-12-18 | 1999-10-21 | Minnesota Mining And Mfg. Co., Saint Paul | Mehrschichtige sperrstrukturen |
| EP0553769B1 (de) | 1992-01-29 | 1996-01-03 | FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG | Ballspielschläger, insbesondere Tennisschläger |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| JP2016505012A (ja) * | 2013-01-10 | 2016-02-18 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| EP3079682A4 (en) * | 2013-12-13 | 2017-08-30 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| EA039043B1 (ru) * | 2015-04-22 | 2021-11-25 | Райджел Фармасьютикалз, Инк. | Пиразольные соединения и способ получения и применения данных соединений |
| BR112018000624A2 (pt) * | 2015-07-15 | 2018-09-18 | Aurigene Discovery Technologies Limited | compostos de indazol e azaindazol como inibidores de irak-4 |
| JP6994454B2 (ja) * | 2015-08-04 | 2022-01-14 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ベンズアゾール化合物ならびに該化合物の作製方法および使用方法 |
| CA3068305A1 (en) * | 2017-06-29 | 2019-01-03 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and methods for making and using |
-
2018
- 2018-06-28 CA CA3068305A patent/CA3068305A1/en active Pending
- 2018-06-28 EP EP18743281.0A patent/EP3645525A1/en not_active Withdrawn
- 2018-06-28 US US16/022,323 patent/US10590121B2/en active Active
- 2018-06-28 WO PCT/US2018/040021 patent/WO2019006126A1/en not_active Ceased
- 2018-06-28 CN CN201880052620.6A patent/CN111032642B/zh not_active Expired - Fee Related
- 2018-06-28 JP JP2019572355A patent/JP7167069B2/ja active Active
-
2020
- 2020-02-12 US US16/789,131 patent/US11059814B2/en active Active
-
2021
- 2021-06-08 US US17/341,817 patent/US20210309655A1/en not_active Abandoned
-
2022
- 2022-10-26 JP JP2022171152A patent/JP7379639B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11059814B2 (en) | 2021-07-13 |
| US20190002455A1 (en) | 2019-01-03 |
| EP3645525A1 (en) | 2020-05-06 |
| JP2020526498A (ja) | 2020-08-31 |
| JP7379639B2 (ja) | 2023-11-14 |
| US20200181135A1 (en) | 2020-06-11 |
| CN111032642B (zh) | 2023-07-18 |
| WO2019006126A1 (en) | 2019-01-03 |
| CN111032642A (zh) | 2020-04-17 |
| JP2023011726A (ja) | 2023-01-24 |
| US10590121B2 (en) | 2020-03-17 |
| US20210309655A1 (en) | 2021-10-07 |
| JP7167069B2 (ja) | 2022-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11059814B2 (en) | Kinase inhibitors and methods for making and using | |
| KR102808215B1 (ko) | Rip1 억제 화합물 및 이를 제조하고 사용하는 방법 | |
| US12043620B2 (en) | Benzazole compounds and methods for making and using the compounds | |
| EP3532465B1 (en) | Pyrazole amide compounds as irak inhibitors | |
| IL278416B1 (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| US11993594B2 (en) | IRAK inhibitors and method for making and using | |
| HK40013639B (en) | Oxazole derivatives for use as irak inhibitors and method for their preparation | |
| HK40013639A (en) | Oxazole derivatives for use as irak inhibitors and method for their preparation | |
| HK40013987A (en) | Pyrazole amide compounds as irak inhibitors | |
| HK40013987B (en) | Pyrazole amide compounds as irak inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230622 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240819 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20241219 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251229 |